Dr. Sandler on Clinical Trials for Liase Inhibitors

Video

Howard M. Sandler, MD, MS from Cedars-Sinai Medical Center Talks About Clinical Trials for Liase Inhibitors

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD
Related Content
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
Stephen J. Freedland, MD

Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC

May 4th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
prostate cancer

Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

May 3rd 2024
Article
18F-PSMA-1007 PET/CT in Prostate Cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer

May 3rd 2024
Article